Evidence map›Paper›PMID 42599510›Full record

ArticleBioprocess and biosystems engineering2026

Automated high-throughput screening combined with model-assisted analysis enables quantitative identification of process drivers and trade-offs during extracellular Fab production in Escherichia coli.

Fabian Schröder-Kleeberg, Lucas Kaspersetz, Sanchir Anar Neff, Markus Zoellkau, Markus Glaser, Markus Brunner, Christian Bosch, Mariano Nicolas Cruz Bournazou, Peter Neubauer

Abstract read
In one paragraph

Article in Bioprocess and biosystems engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Fabian Schröder-KleebergDepartment of Bioprocess Engineering, Institute of Biotechnology, Technische Universität Berlin, Ackerstr. 76, 13355, Berlin, Germany.ORCID http://orcid.org/0009-0006-0358-2984
Lucas KaspersetzDepartment of Bioprocess Engineering, Institute of Biotechnology, Technische Universität Berlin, Ackerstr. 76, 13355, Berlin, Germany.ORCID http://orcid.org/0009-0006-3867-1354
Sanchir Anar NeffDepartment of Bioprocess Engineering, Institute of Biotechnology, Technische Universität Berlin, Ackerstr. 76, 13355, Berlin, Germany.
Markus ZoellkauWacker Biotech GmbH, 07745, Jena, Germany.
Markus GlaserWacker Biotech GmbH, 07745, Jena, Germany.
Markus BrunnerWacker Chemie AG, 81379, München, Germany.
Christian BoschWacker Chemie AG, 81379, München, Germany.
Mariano Nicolas Cruz BournazouDepartment of Bioprocess Engineering, Institute of Biotechnology, Technische Universität Berlin, Ackerstr. 76, 13355, Berlin, Germany.ORCID http://orcid.org/0000-0001-9461-4414
Peter NeubauerDepartment of Bioprocess Engineering, Institute of Biotechnology, Technische Universität Berlin, Ackerstr. 76, 13355, Berlin, Germany. peter.neubauer@tu-berlin.de.ORCID http://orcid.org/0000-0002-1214-9713

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Production of Fab antibody fragments with Escherichia coli strains engineered for extracellular product release can reduce downstream processing requirements but often compromises cellular integrity, resulting in increased cell lysis. To investigate the balance between product formation, product release, and cellular robustness, 32 fed-batch cultivation conditions spanning six process parameters were systematically evaluated in automated high-throughput bioreactors. In total, 100 cultivations were performed, and mechanistic modeling was applied to estimate cell lysis, product formation, and product release kinetics. The combined experimental and model-based analysis revealed a pronounced trade-off between productivity and robustness. Conditions yielding high Fab titers showed minimal cell lysis rates but also slow product release, whereas elevated release kinetics were consistently associated with substantial lysis and reduced Fab titers. Induction strength emerged as the primary driver for maximizing Fab titer, while production temperature governed the balance between product release and cell lysis. Compared to the reference condition, Fab titers increased approximately twofold to 730 mg L[Formula: see text] while reducing the cell lysis rate by up to eightfold to near-negligible levels, albeit at the expense of a 2.2-fold lower product release rate. Robustness studies under large-scale-relevant conditions identified moderate substrate heterogeneities as an additional factor enhancing productivity while reducing cell lysis. Furthermore, the extensive dataset enabled refinement of a previously developed product model by introducing an induction-strength-dependent production load and provided mechanistic insight into the relationship between product release and cell lysis. Overall, the study demonstrates how mechanistic modeling enhances the interpretation of automated high-throughput screening experiments by linking observable process responses to underlying physiological behavior and enabling quantitative analysis of complex production trade-offs.

Indexed as

BioreactorsEscherichia coliHigh-Throughput Screening AssaysImmunoglobulin Fab FragmentsModels, BiologicalImmunoglobulin Fab FragmentsFab antibody productionFed-batch cultivationHigh-throughput bioprocess developmentLeaky Escherichia coliMechanistic modelingProcess optimization

Identifiers

PMID42599510
PMCPMC13582191

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.